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We are pleased that Friães et al. have elected to examineemm89 strains in Portugal (1); it was our hope that other
groups would evaluate emm89 strains from elsewhere, using either
whole-genome sequencing (WGS) or the PCR method that we
described in our report (2). Subsequent to our publication (2),
Zhu et al. used WGS to identify variants of the nga-slo promoter
among emm89 isolates in the United States, Finland, and Iceland
(3) indicative of the new emergent emm89 clade in these coun-
tries. Although they did not use WGS, Friães et al. demonstrated
that it is likely that the emergent emm89 clade that we identified in
the United Kingdom and elsewhere is also present in Portugal (1).
Friães and colleagues have noted that the focus on different
aspects of emm89 strains in the various studies (2–4) makes it hard
to determine if the same clade had disseminated in different re-
gions. In our original report, we aimed to provide a single com-
prehensive description of all six regions of recombination that
characterize this emergent emm89 clade (2). Two of these regions,
the nga-slo locus (region 2) and the hasABC capsule locus (region
6), were highlighted because of their phenotypic significance; it
was beyond the scope of our paper to undertake in-depth analysis
of all of the regions. We did, however, clearly demonstrate en-
hanced NGA-SLO toxin expression and stated that this could be
due to a single polymorphism or several polymorphisms within
the nga-slo locus and promoter or elsewhere in the genome. In-
deed, it may be misleading to focus on a single region or multiple
regions of recombination without understanding of the collective
impact of all of the changes. In our sampling of the emm89 pop-
ulation, we failed to identify isolates with an intermediate number
of recombination regions, raising the possibility that all six re-
modeled regions promoted the success of this lineage, not simply
the two that have been highlighted.
To more clearly illustrate the emergence of the new emm89
clade, we combined WGS data from isolates from the United
States, Finland, and Iceland reported by Zhu et al. (3) for which we
could confidently determine the sequence type (ST) (n  737)
with our data for United Kingdom and Swiss strains (2) (n 131).
We identified three distinct lineages (Fig. 1A) that are linked to the
three previously identified nga-slopromoter variants (3). In agree-
ment with Friães et al., the original United Kingdom emm89 pop-
ulation lineage (with nga-slo promoter “variant 2”) and the emer-
gent acapsular emm89 clade (with nga-slo promoter “variant 3”)
are both predominantly ST101; any ST variants within this clade
are limited to single-locus variants. Isolates from Finland and Ice-
land, with a few minor exceptions, clustered either with the orig-
inal United Kingdom emm89 ST101 lineage or with the new emer-
gent ST101 clade described in our original paper (2). The majority
of isolates from the United States, however, clustered either with
the third identified lineage (with nga-slo promoter “variant 1”),
dominated by ST407 and ST803, or with the new emergent ST101
clade. It appears that, as in our original findings in the United
Kingdom, prior to 2007 to 2008, the dominant emm89 lineage in
European countries was an ST101-like lineage but that the domi-
nant lineage in the United States was an ST407/ST803-like lineage.
Since 2007 to 2008, the new emergent variant, highly likely to have
arisen within the ST101 background through recombination, has
risen to dominance in both Europe and the United States. All
members of this emergent clade have the same six regions of re-
combination, of which the nga-slo and hasABC regions are just
two.
The ST407/ST803-like lineage sequenced by Zhu et al. (3) was
infrequent in European countries and is separated from the two
ST101-like lineages by a high level of core single nucleotide poly-
morphisms (SNPs) (Fig. 1A). In comparison to the emm89 H293
reference (ST101), this lineage contains its own distinct predicted
pattern of recombination (Fig. 1B). Given the level of difference
between ST101 and ST407/ST803, the success of the ST101 emer-
gent clade in both North America and Europe may therefore re-
flect a more general competitive advantage of this new lineage.
The findings also highlight a propensity of the genetic background
of emm89 to undergo recombination.
We agree that the emergent clade has most likely acquired a
competitive advantage through enhanced transmission and/or a
propensity for superficial infections. In 2009, a year when the in-
cidence of emm89 invasive infections peaked in the United King-
dom (2), emm89 accounted for 16% of all 135 noninvasive Strep-
tococcus pyogenes isolates submitted in April to November to our
clinical laboratory (which serves a population of approximately 2
million) and 13% of 125 invasive S. pyogenes isolates submitted in
January to November within London to the national reference
laboratory. This contrasted with emm1 strains, where a dispropor-
tionately high number accounted for invasive isolates (23%) com-
pared with noninvasive isolates (11%) during the same time peri-
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ods (unpublished data). At present, there are no experimental
data that directly compare the invasiveness of the emergent clade
with that of previous emm89 lineages. Using population-based
mortality data, we found no evidence that the emergent emm89 clade,
where associated with invasive infection, caused greater mortality
than the original ST101 lineage in the United Kingdom (2).
The potential for certain lineages of S. pyogenes to undergo
extensive recombination is of wider significance. It seems likely
that future vaccines and/or diagnostic tests will target genes and
gene products thought to be crucial for pathogenesis, and yet we
have demonstrated that, at least in emm89, some factors can be
lost or dramatically altered. The mechanisms explaining why and
FIG 1 Phylogenetic analysis of emm89 population. (A) Three lineages were identified in the emm89 population based on the maximum likelihood phylogeny
of SNPs identified after mapping to the H293 reference strain of the sequences of 868 emm89 strains from both the United Kingdom study (2) and the United
States/Finland/Iceland study (3), where ST could be confidently assigned. We identified 16 sequence types (ST101, n 621; ST407, n 160; ST580, n 3; ST791,
n 2; ST792 to ST800, n 1 each; ST801, n 20; ST802, n 1; ST803, n 52). Two lineages were equivalent to those in the United Kingdom study (2) which
identified an emergent clade type (red) from a previous lineage (blue) where the major ST was ST101 with some single-locus variants (identified in parentheses).
These lineages are also associated with the previously termed capsular nga-slo promoter “variant 2” strains (blue) and acapsular nga-slo promoter “variant 3”
strains (red). A third lineage (black) was also identified, representing ST407 and ST803 and two other sequence type variants (ST795 and ST799), equivalent to
the previously termed capsular nga-slo promoter “variant 1” strains. (B) Regions of recombination in a subset of 68 strains representing all of the sequence types
identified compared to the reference strain H293 (ST101) were predicted using Gubbins (5). Branch colors represent lineages and sequence types. Emergent
variant ST101 (red) and other single-locus variants (indicated with an asterisk [*]) are shown in the following order from the top of the tree: ST791 (maroon),
ST802 (orange), ST796 (yellow), ST801 (pink), ST798 (dark red), ST792 (purple), ST580 (green), ST793 (lilac), ST794 (grey-purple), ST800 (bright pink).
Previously dominant “European” variant ST101 (blue) and single-locus variant ST797 (pale blue) are shown, as are previously dominant “United States” variants
ST407 (black) and ST803 (grey) and single-locus variants ST799 (pale grey) and ST795 (brown). Regions of recombination identified in each strain are shown
as vertical red lines (indicating recombination on internal nodes) or blue lines (indicating recombination on terminal branches), and genome coordinates are
given on the bottom line (turquoise). The six previously identified regions of recombination (R1 to R6) were present in the emergent clade strains of ST101 and
other single-locus variants within this lineage, along with a variation in the clustered regularly interspaced short palindromic repeat (CRISPR) region (column
C) (2). The United States variant ST407/ST803 lineage had several large regions of predicted recombination compared to the H293 reference strain, including one
region which encompassed the MLST yqil locus and introduced the sequence type variation.
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how these strains undergo recombination-related genome re-
modeling have not been determined but clearly require recogni-
tion and further evaluation.
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